Recruiting studies: Post Essential Thrombocythemia Myelofibrosis Post Et Mf

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel
Phase N/A · 2 location(s) · MPN Research Foundation · NCT07362225 Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Resp
Phase 3 · 215 location(s) · Kartos Therapeutics, Inc. · NCT06479135 Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal
Phase 1/Phase 2 · 19 location(s) · Telios Pharma, Inc. · NCT05280509 Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
Phase 1 · 7 location(s) · Novartis Pharmaceuticals · NCT07340138 Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
Phase 2 · 9 location(s) · Icahn School of Medicine at Mount Sinai · NCT05835466 Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibr
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06327100

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.